Abstract
Detection of chromosomal abnormalities is important for cancer patients. Compared to common cancer cytogenetics methods including karyotype, fluorescent in-situ hybridization (FISH), and chromosomal microarray (CMA), optical genome mapping (OGM) is an innovative method to detect CA. The objective of this pilot study was to determine a stepwise approach to adopt OGM in the clinical setting. Blinded study was used to compare OGM, karyotype, FISH, and CMA on five well-characterized cancer cases (four leukemia/lymphoma and one solid tumor).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
